The partial inhibitor of hepatic SCD1, aramchol, is a conjugate of cholic acid and arachidic acid, and is currently the most advanced drug candidate for NASH among those targeting hepatic DNL. Here, SCD is linked to metabolic dysfunction-associated steatohepatitis.